Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

NCT03993379 is registered in ClinicalTrials.gov with CytomX Therapeutics as lead sponsor.

NCT NCT03993379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03993379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Lead sponsor
CytomX Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
November 20, 2019
Completion date
May 21, 2020
Enrollment
3 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, unresectable or metastatic melanoma